Cidofovir dihydrate

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

西多福韦二磷酸酯的前药，通过选择性抑制病毒 DNA 聚合酶来抑制巨细胞病毒 (CMV) 病毒复制。

The prodrug of cidofovir diphosphate that inhibits cytomegalovirus (CMV) viral replication by selectively inhibiting viral DNA polymerases; also incorporates itself into viral DNA hence inhibiting viral DNA synthesis during reproduction.CMV Infection Approved.

Cidofovir (5-100 μM, 72 hours) dihydrate has antiviral activity against feline herpesvirus type-1 (FHV-1) with an IC50 of 11 μM, and can reduce Crandell-Reese feline kidney cells counts in a dose dependent manner. Cidofovir (10-1000 μM, 24-120 hours) dihydrate can reduce cancer cell viability and induces apoptosis.Cell Cytotoxicity Assay Cell Line:Crandell-Reese feline kidney(CRFK) cellsConcentration:10-100 μM Incubation Time:72 hours Result:Reduced CRFK cells by 9.1%.Cell Viability Assay Cell Line:Caco-2, FTC-133, HeLa, Hep-G2, MDA-MB-231, NCI-H1975 and PC-3 cells Concentration:10-1000 μM Incubation Time:24, 48, 72, 96, 120 hours Result:Resulted in a gradual decrease in tumor cell viability with time and concentration increasing and inhibited the number of FTC-133 cell clones by about 55% at 100 μM comparing to the untreated group.Apoptosis Analysis Cell Line:FTC-133 cells Concentration:100 μM Incubation Time:96 hours Result:Showed a significant increase in the expression of pro-apoptotic proteins, such as cytochrome c, phospho-p53 (S15) and caspase-3 by 130%, 49%, and 46%, respectively while the anti-apoptotic protein Bcl-x decreased significantly by 57% comparing to the untreated cells.

Cidofovir (subcutaneous injection, 100 mg/kg, 3-6 days interval, 21 days)dihydrate is highly protective against death from cowpox virus (CPV) infection at high doses in female weanling BALB/c mice. Animal Model:Female weanling BALB/c mice infected with cowpox virus (CPV)Dosage:100 mg/kg Administration:Subcutaneous injection; 3-6 days interval; 21 days Result:Prevented 80-100% of mouse deaths when administered on the first 4-3 days before infection.Protected 35-50% of mice when administered on the fourth day after infection, and 10-20% when administered on the sixth day.

HPMPC dihydrate | (S)-HPMPC dihydrate

Microbiology/Virology

CMV

CMV

Infection

CMV Infection

149394-66-1

315.2176

C8H18N3O8P

>98% (HPLC)

10 mM in DMSO

C1=CN(C(=O)N=C1N)CC(CO)OCP(=O)(O)O.O.O

Phosphonic acid, P-[[(1S)-2-(4-amino-2-oxo-1(2H)-pyrimidinyl)-1-(hydroxymethyl)ethoxy]methyl]-, hydrate (1:2)

(-20℃)

With Ice Pack

≥ 2 years